Matches in SemOpenAlex for { <https://semopenalex.org/work/W3003308809> ?p ?o ?g. }
- W3003308809 endingPage "478" @default.
- W3003308809 startingPage "467" @default.
- W3003308809 abstract "There is a need for improved methods for detection and risk stratification of myocarditis associated with immune checkpoint inhibitors (ICIs). Global longitudinal strain (GLS) is a sensitive marker of cardiac toxicity among patients receiving standard chemotherapy. There are no data on the use of GLS in ICI myocarditis. This study sought to evaluate the role of GLS and assess its association with cardiac events among patients with ICI myocarditis. This study retrospectively compared echocardiographic GLS by speckle tracking at presentation with ICI myocarditis (cases, n = 101) to that from patients receiving an ICI who did not develop myocarditis (control subjects, n = 92). Where available, GLS was also measured pre-ICI in both groups. Major adverse cardiac events (MACE) were defined as a composite of cardiogenic shock, arrest, complete heart block, and cardiac death. Cases and control subjects were similar in age, sex, and cancer type. At presentation with myocarditis, 61 cases (60%) had a normal ejection fraction (EF). Pre-ICI, GLS was similar between cases and control subjects (20.3 ± 2.6% vs. 20.6 ± 2.0%; p = 0.60). There was no change in GLS among control subjects on an ICI without myocarditis (pre-ICI vs. on ICI, 20.6 ± 2.0% vs. 20.5 ± 1.9%; p = 0.41); in contrast, among cases, GLS decreased to 14.1 ± 2.8% (p < 0.001). The GLS at presentation with myocarditis was lower among cases presenting with either a reduced (12.3 ± 2.7%) or preserved EF (15.3 ± 2.0%; p < 0.001). Over a median follow-up of 162 days, 51 (51%) experienced MACE. The risk of MACE was higher with a lower GLS among patients with either a reduced or preserved EF. After adjustment for EF, each percent reduction in GLS was associated with a 1.5-fold increase in MACE among patients with a reduced EF (hazard ratio: 1.5; 95% confidence interval: 1.2 to 1.8) and a 4.4-fold increase with a preserved EF (hazard ratio: 4.4; 95% confidence interval: 2.4 to 7.8). GLS decreases with ICI myocarditis and, compared with control subjects, was lower among cases presenting with either a preserved or reduced EF. Lower GLS was strongly associated with MACE in ICI myocarditis presenting with either a preserved or reduced EF." @default.
- W3003308809 created "2020-02-07" @default.
- W3003308809 creator A5001690601 @default.
- W3003308809 creator A5001986733 @default.
- W3003308809 creator A5003207387 @default.
- W3003308809 creator A5008479799 @default.
- W3003308809 creator A5013973845 @default.
- W3003308809 creator A5016136470 @default.
- W3003308809 creator A5017768167 @default.
- W3003308809 creator A5020975306 @default.
- W3003308809 creator A5022062612 @default.
- W3003308809 creator A5023615361 @default.
- W3003308809 creator A5026811038 @default.
- W3003308809 creator A5028049778 @default.
- W3003308809 creator A5031050771 @default.
- W3003308809 creator A5031475597 @default.
- W3003308809 creator A5032297344 @default.
- W3003308809 creator A5035343389 @default.
- W3003308809 creator A5036152028 @default.
- W3003308809 creator A5036723444 @default.
- W3003308809 creator A5040652983 @default.
- W3003308809 creator A5046320640 @default.
- W3003308809 creator A5046873167 @default.
- W3003308809 creator A5047137718 @default.
- W3003308809 creator A5047828139 @default.
- W3003308809 creator A5048185686 @default.
- W3003308809 creator A5048351158 @default.
- W3003308809 creator A5049264533 @default.
- W3003308809 creator A5049839632 @default.
- W3003308809 creator A5058198634 @default.
- W3003308809 creator A5059805173 @default.
- W3003308809 creator A5061316252 @default.
- W3003308809 creator A5063519328 @default.
- W3003308809 creator A5066688363 @default.
- W3003308809 creator A5068688393 @default.
- W3003308809 creator A5068710430 @default.
- W3003308809 creator A5075396473 @default.
- W3003308809 creator A5077189358 @default.
- W3003308809 creator A5082020218 @default.
- W3003308809 creator A5084442880 @default.
- W3003308809 creator A5087164932 @default.
- W3003308809 creator A5087233869 @default.
- W3003308809 creator A5087570594 @default.
- W3003308809 creator A5090606294 @default.
- W3003308809 date "2020-02-01" @default.
- W3003308809 modified "2023-10-12" @default.
- W3003308809 title "Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis" @default.
- W3003308809 cites W148860973 @default.
- W3003308809 cites W1870638042 @default.
- W3003308809 cites W1961248591 @default.
- W3003308809 cites W1968148627 @default.
- W3003308809 cites W2002312306 @default.
- W3003308809 cites W2006714833 @default.
- W3003308809 cites W2014771460 @default.
- W3003308809 cites W2047100993 @default.
- W3003308809 cites W2068483637 @default.
- W3003308809 cites W2107849529 @default.
- W3003308809 cites W2116917468 @default.
- W3003308809 cites W2125123447 @default.
- W3003308809 cites W2127407420 @default.
- W3003308809 cites W2133304247 @default.
- W3003308809 cites W2138601833 @default.
- W3003308809 cites W2140921081 @default.
- W3003308809 cites W2142877037 @default.
- W3003308809 cites W2149445224 @default.
- W3003308809 cites W2154066911 @default.
- W3003308809 cites W2530921721 @default.
- W3003308809 cites W2547133566 @default.
- W3003308809 cites W2548138649 @default.
- W3003308809 cites W2615795621 @default.
- W3003308809 cites W2623421406 @default.
- W3003308809 cites W2736166064 @default.
- W3003308809 cites W2748488194 @default.
- W3003308809 cites W2789315292 @default.
- W3003308809 cites W2795067517 @default.
- W3003308809 cites W2800087803 @default.
- W3003308809 cites W2803500132 @default.
- W3003308809 cites W2803674135 @default.
- W3003308809 cites W2804734521 @default.
- W3003308809 cites W2888880602 @default.
- W3003308809 cites W2893073939 @default.
- W3003308809 cites W2929415048 @default.
- W3003308809 cites W3158326626 @default.
- W3003308809 cites W36650246 @default.
- W3003308809 cites W4367664545 @default.
- W3003308809 doi "https://doi.org/10.1016/j.jacc.2019.11.049" @default.
- W3003308809 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7067226" @default.
- W3003308809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32029128" @default.
- W3003308809 hasPublicationYear "2020" @default.
- W3003308809 type Work @default.
- W3003308809 sameAs 3003308809 @default.
- W3003308809 citedByCount "162" @default.
- W3003308809 countsByYear W30033088092020 @default.
- W3003308809 countsByYear W30033088092021 @default.
- W3003308809 countsByYear W30033088092022 @default.
- W3003308809 countsByYear W30033088092023 @default.
- W3003308809 crossrefType "journal-article" @default.
- W3003308809 hasAuthorship W3003308809A5001690601 @default.